安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Homepage | Fintepla HCP
Learn about FINTEPLA®, a treatment for seizures associated with Dravet syndrome and LGS, and get full Prescribing Information, including Boxed Warning
- FINTEPLA® (fenfluramine) | Official Patient Website
FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older It is not known if FINTEPLA is safe and effective in children less than 2 years of age
- Fintepla: Uses, Instructions, Side Effects, Warnings
Fintepla (fenfluramine) is used for the treatment of seizures associated with Dravet syndrome Includes Fintepla side effects, interactions and indications
- Fenfluramine - Epilepsy Foundation
Fenfluramine is the generic name (non-brand name) of a seizure medicine with the brand name Fintepla® from Zogenix
- Fintepla: Side effects, cost, dosage, uses, interactions, and . . .
Fintepla (fenfluramine) is a prescription oral solution that treats seizures in adults and some children with epilepsy Learn about side effects, dosage, and more
- Fintepla (fenfluramine): Uses, Side Effects, Dosage Reviews
Fintepla (fenfluramine) is an antiepileptic (antiseizure) medication that's used for people ages 2 years and older This medication is only meant for those with seizures caused by Dravet syndrome or Lennox-Gastaut syndrome, not other seizure conditions Fintepla (fenfluramine) comes as an oral solution, so it's a good option for people who can't swallow pills
- Fintepla (fenfluramine) - Uses, Side Effects, and More
Overview: Fintepla is used to treat certain types of seizures It may work by blocking certain signals that come from nerves and cause seizures Common side effects include weight loss, sleepiness
- U. S. FDA Approves FINTEPLA[®] (fenfluramine) Oral Solution . . .
FINTEPLA® (fenfluramine) oral solution is a prescription medication approved by the FDA and authorized by the EU Commission, and under regulatory review with the PMDA (Japan), for the treatment of seizures associated with Dravet syndrome in patients two years of age and older 8,12 A Type II Variation Application has also been submitted to the
|
|
|